Skip to main content

Courtney Breen

Stock Analyst at Bernstein

Total Price Targets
7
Stocks Covered
5
Sectors
Healthcare
Most Recent
Feb 11, 2026

Notable Calls (Last 12 Months)

Most Bullish

  • PFE+22.7%
    Pfizer Inc.
    $30.00 targetOct 31, 2025
  • GILD+8.4%
    Gilead Sciences, Inc.
    $135.00 targetDec 29, 2025
  • GILD+2.9%
    Gilead Sciences, Inc.
    $160.00 targetFeb 11, 2026

Most Bearish

  • GILD+2.9%
    Gilead Sciences, Inc.
    $160.00 targetFeb 11, 2026
  • GILD+8.4%
    Gilead Sciences, Inc.
    $135.00 targetDec 29, 2025
  • PFE+22.7%
    Pfizer Inc.
    $30.00 targetOct 31, 2025

Stocks Covered by Courtney Breen

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
GILDGilead Sciences, Inc.$160.00$132.04+21.2%2Feb 11, 2026
PFEPfizer Inc.$30.00$26.38+13.7%2Oct 31, 2025
MRKMerck & Co., Inc.$110.00$111.89-1.7%1Dec 2, 2024
ABBVAbbVie Inc.$203.00$206.29-1.6%1Oct 17, 2024
MRNAModerna, Inc.$55.00$44.65+23.2%1Oct 17, 2024

Recent Activity

  • Feb 11, 2026— Set$160.00price target onGILD(Gilead Sciences, Inc.)
  • Dec 29, 2025— Set$135.00price target onGILD(Gilead Sciences, Inc.)
  • Oct 31, 2025— Set$30.00price target onPFE(Pfizer Inc.)
  • Dec 2, 2024— Set$110.00price target onMRK(Merck & Co., Inc.)
  • Oct 17, 2024— Set$55.00price target onMRNA(Moderna, Inc.)
  • Oct 17, 2024— Set$32.00price target onPFE(Pfizer Inc.)
  • Oct 17, 2024— Set$203.00price target onABBV(AbbVie Inc.)

Frequently Asked Questions

Who is Courtney Breen?

Courtney Breen is a stock analyst at Bernstein covering 5 stocks primarily in Healthcare. They have issued 7 price targets since Oct 17, 2024.

What stocks does Courtney Breen cover?

Courtney Breen currently covers 5 stocks, including GILD, PFE, MRK, ABBV, MRNA.

What is Courtney Breen's latest price target?

Courtney Breen's most recent price target was $160.00 on GILD (Gilead Sciences, Inc.), set on Feb 11, 2026.

What is Courtney Breen's highest price target?

Courtney Breen's highest issued price target is $203.00 on ABBV, set on Oct 17, 2024.

Coverage based on publicly published price targets. Not investment advice.